This HTML5 document contains 64 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00689/identifier/pubchem-compound/
dctermshttp://purl.org/dc/terms/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00689/identifier/pubchem-substance/
n14http://linked.opendata.cz/resource/drugbank/company/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00689/identifier/kegg-drug/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00689/identifier/drugbank/
n13http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n15http://linked.opendata.cz/resource/drugbank/drug/DB00689/identifier/chemspider/
n10http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n7http://linked.opendata.cz/resource/drugbank/drug/DB00689/identifier/wikipedia/
xsdhhttp://www.w3.org/2001/XMLSchema#
n8http://linked.opendata.cz/resource/drugbank/drug/DB00689/identifier/pharmgkb/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00689/identifier/kegg-compound/

Statements

Subject Item
n2:DB00689
rdf:type
n3:Drug
n3:description
A cephalorsporin antibiotic that is no longer commonly used.
n3:generalReferences
# Tune BM, Hsu CY: The renal mitochondrial toxicity of beta-lactam antibiotics: in vitro effects of cephaloglycin and imipenem. J Am Soc Nephrol. 1990 Nov;1(5):815-21. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2133431 # Tune BM, Fravert D, Hsu CY: Oxidative and mitochondrial toxic effects of cephalosporin antibiotics in the kidney. A comparative study of cephaloridine and cephaloglycin. Biochem Pharmacol. 1989 Mar 1;38(5):795-802. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2930580
n3:group
approved
n3:indication
For treatment of severe infections caused by susceptible bacteria.
n3:manufacturer
n14:271B45BE-363D-11E5-9242-09173F13E4C5
owl:sameAs
n10:DB00689 n13:DB00689
dcterms:title
Cephaloglycin
adms:identifier
n7:Cephaloglycin n8:PA164781027 n11:DB00689 n12:C13440 n15:18069 n16:46506850 n17:D01949 n18:19150
n3:mechanismOfAction
The bactericidal activity of cephaloglycin results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs).
n3:synonym
Cefaloglycine D-Cephaloglycine 7-(D-2-Amino-2-phenylacetamido)-3-acetoxymethyl-delta(sup3)-cephem-4-carboxylic acid 7-(D-alpha-Aminophenyl-acetamido)cephalosporanic acid Cephaoglycin acid CEG Cefaloglycinum D-(-)-Cephaloglycin 7-(2-D-alpha-Aminophenylacetamido)cephalosporanic acid Cephaloglycine Cefaloglicina
n3:toxicity
Adverse effects following overdosage include nausea, vomiting, epigastric distress, diarrhea, and convulsions.
n3:synthesisReference
Wall, W.F., Fatherey, M. and Boothroyd, 6.; U.S. Patent 3,422,103; January 14,1969; assigned to Glaxo Laboratories, Ltd. Pfeiffer, R.R. and Bottorff, E.M.; US. Patent 3,497,505; February 24,1970; assigned to Eli Lilly & Co. Jackson, B.G.; U.S. Patent 3,671,449; June 20,1972; assigned to Eli Lilly & Co.
n3:IUPAC-Name
n4:271B45C3-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B45C9-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B45C8-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B45C5-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B45C6-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B45C7-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B45D9-363D-11E5-9242-09173F13E4C5 n4:271B45C1-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B45DB-363D-11E5-9242-09173F13E4C5 n4:271B45BF-363D-11E5-9242-09173F13E4C5 n4:271B45C2-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B45C0-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B45CF-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B45D0-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B45CA-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B45CB-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B45CD-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B45CC-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B45CE-363D-11E5-9242-09173F13E4C5
n3:absorption
Well absorbed following oral administration.
n3:affectedOrganism
Enteric bacteria and other eubacteria
n3:casRegistryNumber
3577-01-3
n3:category
n3:Bioavailability
n4:271B45D5-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B45D7-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B45D8-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B45DA-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B45D4-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B45D3-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B45D6-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B45C4-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B45D1-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B45D2-363D-11E5-9242-09173F13E4C5